

ENQ-38891-J5G4K1

24 June 2020

██████████
██████████
GE Free NZ in Food and Environment

Via: ██████████

Private Bag 632
Wellington 6140, New Zealand

Level 10, Grant Thornton House
215 Lambton Quay
Wellington 6011, New Zealand

epa.govt.nz
+64 4 916 2426

Official Information Act Request

Dear ██████████

I refer to your request received on 2 June 2020, for the following information:

“1. Please may we have the annual reports of the years 2016-2019 for the SillaJen Biotherapeutics Inc trial (App202601) as specified in the EPA decision under control 7.

2. Were there any reported compliance issues related to the SillaJen Biotherapeutics (AP202601) trial?

3. Please can we have a timeline as to when the trial is expected to be concluded?

We wish to be notified when any application of a viable genetically modified medical or veterinary procedure or product is made in the future.”

Please find attached the information requested. The list of Annual reports provided to EPA from SillaJen Biotherapeutics from 2016 – 2019:

- APP202601_2016_Annual_Report.pdf (6 Months)
- APP202601_2017_Annual_Report.pdf
- APP202601_2018_Annual_Report.pdf
- APP202601_2020_Annual_Report_Final.pdf.

There were no reported compliance issues relating to the SillaJen Biotherapeutics trial.

The trial came to an end in August 2019.

We will not be notifying you of any future application for “viable genetically modified medical or veterinary procedure or product” as these are publically available on EPA’s website. I have provided the website address below for your information and review.

<https://www.epa.govt.nz/public-consultations/in-progress/>

You have the right to seek an investigation and review of this decision by the Ombudsman. You can contact the Ombudsman on 0800 802 602, or by email at info@ombudsman.parliament.nz.

If you have any further queries, please do not hesitate to contact us via ministerials@epa.govt.nz.

Yours sincerely

A handwritten signature in black ink, appearing to read 'C. Ehlers', with a long horizontal flourish extending to the right.

Dr Clark Ehlers
Acting General Manager
Hazardous Substance and New Organisms